Multimarker proteomic profiling for the prediction of cardiovascular mortality in patients with chronic heart failure

Gilles Lemesle1, Fleur Maury2, Olivia Beseme3

  • 1INSERM UMR1167, Lille, France; Institut Pasteur de Lille, Lille, France; Université Lille Nord de France, Lille, France; Centre Hospitalier Régional et Universitaire de Lille, Lille, France; Faculté de Médecine de Lille, Lille, France.

Plos One
|April 24, 2015
PubMed

Insights

Plasma proteomic profiling can improve risk stratification for patients with chronic heart failure (HF). This approach helps identify individuals at higher risk of cardiovascular death, potentially guiding treatment decisions.

Area of Science:

  • Biochemistry
  • Cardiology
  • Proteomics

Background:

  • Risk stratification is crucial for managing systolic chronic heart failure (HF) and guiding advanced therapies like cardiac transplantation.
  • Proteomics offers a promising avenue for obtaining prognostic information across various diseases.

Purpose of the Study:

  • To evaluate the utility of plasma proteomic profiling for enhancing risk stratification in patients with systolic HF.
  • To develop and validate proteomic scores for predicting cardiovascular mortality in HF patients.

Main Methods:

  • Plasma samples from 198 systolic HF patients (99 deceased, 99 alive at 3 years) were analyzed using surface-enhanced laser desorption/ionization-time of flight mass spectrometry.
  • Proteomic scores were developed using machine learning algorithms (SVM, SPLS-DA, Lasso logistic regression) based on 42 differentially intense ion peaks.
  • The predictive performance of these scores was assessed in a validation cohort.

Main Results:

  • Proteomic scores were significantly higher in patients who died from cardiovascular causes within 3 years.
  • The developed proteomic scores demonstrated consistent predictive accuracy (AUC 0.66-0.68) across different regression methods.
  • These scores significantly improved the discrimination and reclassification of HF patients regarding cardiovascular mortality, even after adjusting for confounders.

Conclusions:

  • Plasma proteomic analysis holds potential for improving cardiovascular risk prediction in patients with systolic HF.
  • Proteomic profiling can aid clinicians in identifying high-risk individuals who may benefit from closer monitoring or intensified therapeutic strategies.